Xanthine

Xanthine

SCHEMBL133793

O=c1[nH]c(=O)c2[nH]cnc2[nH]1.OC[C@H]1OC(O)[C@H](O)[C@@H]1O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.59
GDA Q9Y2T3 1/20 0.59
PNP P00491 4/20 0.43
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HPGD P15428 1/20 0.36
MAPT P10636 1/20 0.35
CDA P32320 1/20 0.35
PYGM P11217 3/20 0.35
PAX8 Q06710 1/20 0.35
SLC28A1 O00337 1/20 0.34
SLC28A2 O43868 1/20 0.34
SLC29A1 Q99808 1/20 0.34
SLC28A3 Q9HAS3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Xanthine SCHEMBL11134143 1.00 ACHE (0.59) ACHEGDAPNPMEN1KMT2A
Xanthine SCHEMBL23067651 0.84 ACHE (0.49) ACHEGDAPNPMEN1KMT2A
Inositol SCHEMBL23881989 0.82 GDA (0.82) ACHEGDAPNP
Uridine SCHEMBL11232088 0.80 SLC28A1 (0.67) SLC28A1SLC28A2SLC29A1SLC28A3
Hypoxanthine SCHEMBL9538156 0.80 ALDH1A1 (0.53) PNPMEN1KMT2AMAPTCDA
Xanthine SCHEMBL2139667 0.77 GDA (0.79) ACHEGDAHPGD
Ribose (Furanose) SCHEMBL16620262 0.77 PNP (0.44) PNPMEN1KMT2AHPGDMAPT
Xanthine SCHEMBL29669592 0.77 GDA (1.00) ACHEGDAPNPHPGDPAX8
Xanthine SCHEMBL4965 0.77 GDA (1.00) ACHEGDAPNPHPGDPAX8
Xanthine SCHEMBL2352524 0.77 GDA (1.00) ACHEGDAPNPHPGDPAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114058572-A Proliferation medium for stem cell 3D simulation culture 华子昂 2022-02-18 CN disclosed
CN-114058571-A Preparation method of proliferation culture medium for stem cell 3D simulation culture 华子昂 2022-02-18 CN disclosed
CN-111418710-A Method for establishing uric acid nephropathy animal model 北京中医药大学 2020-07-17 CN disclosed
US-20180292384-A1 URINE METABOLITE PROFILES IDENTIFY KIDNEY ALLOGRAFT STATUS CORNELL UNIVERSITY 2018-10-11 US disclosed
EP-3302707-A1 URINE METABOLITE PROFILES IDENTIFY KIDNEY ALLOGRAFT STATUS Cornell University (US) 2018-04-11 EP disclosed
WO-2016196329-A1 URINE METABOLITE PROFILES IDENTIFY KIDNEY ALLOGRAFT STATUS CORNELL UNIVERSITY (US) 2016-12-08 WO disclosed
EP-0885192-B8 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN- ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVE, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) 2012-05-16 EP disclosed
EP-0885192-B1 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN- ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVE, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) 2012-03-07 EP disclosed
EP-2311806-A2 Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists The United States of America, Represented by the Secretary, Department of Health and Human Services (US) 2011-04-20 EP disclosed
CN-100410267-C Soybean isoflavone extract, its preparation process and pharmaceutical compositions containing same BEIJING BOTAN BIOTECHNOLOGIES (CN) 2008-08-13 CN disclosed
US-20050119462-A1 Expression vectors and promoters for heterologous gene expression BIOTECNOL SA (PT) 2005-06-02 US disclosed
EP-1461437-A2 EXPRESSION VECTORS AND PROMOTERS FOR HETEROLOGOUS GENE EXPRESSION Biotecnol S.A. (PT) 2004-09-29 EP disclosed
WO-2003056020-A2 EXPRESSION VECTORS AND PROMOTERS FOR HETEROLOGOUS GENE EXPRESSION BIOTECNOL SA (PT) 2003-07-10 WO disclosed
EP-0708781-B1 A 3 ADENOSINE RECEPTOR AGONISTS USA (US) 2001-10-04 EP disclosed
US-6066642-A FOR SELECTIVELY BLOCKING THE A3 ADENOSINE RECEPTOR OF A MAMMAL THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-05-23 US disclosed
EP-0885192-A1 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN- ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVE, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) 1998-12-23 EP disclosed
US-5773423-A XANTHINE RIBOSIDES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1998-06-30 US disclosed
WO-1997027177-A2 DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN-4-ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-07-31 WO disclosed
EP-0708781-A1 A 3 ADENOSINE RECEPTOR AGONISTS THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) 1996-05-01 EP disclosed
WO-1995002604-A1 A3 ADENOSINE RECEPTOR AGONISTS THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1995-01-26 WO disclosed